Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today reported financial results for 2017 and provided a corporate update. As quoted in the press release: “We made significant progress throughout 2017 advancing our pipeline and PDC therapeutic platform both through our own clinical development …

As quoted in the press release:

“We made significant progress throughout 2017 advancing our pipeline and PDC therapeutic platform both through our own clinical development programs and through strategic collaborations. Our Phase 2 study for R/R MM and other B-Cell malignancies continues to move forward and we continue to be pleased with the results of our ongoing Phase 1 clinical trial of CLR 131 as a treatment for advanced MM,” said James Caruso, president and CEO of Cellectar Biosciences. “We expect to achieve a number of important milestones in the coming months that should position us well for continued progress throughout the balance of 2018 and beyond.”